<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-17T19:10:13Z</responseDate><request verb="GetRecord" identifier="oai:www.recercat.cat:10230/70235" metadataPrefix="didl">https://recercat.cat/oai/request</request><GetRecord><record><header><identifier>oai:recercat.cat:10230/70235</identifier><datestamp>2025-04-30T20:02:55Z</datestamp><setSpec>com_2072_6</setSpec><setSpec>col_2072_452952</setSpec></header><metadata><d:DIDL xmlns:d="urn:mpeg:mpeg21:2002:02-DIDL-NS" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="urn:mpeg:mpeg21:2002:02-DIDL-NS http://standards.iso.org/ittf/PubliclyAvailableStandards/MPEG-21_schema_files/did/didl.xsd">
   <d:DIDLInfo>
      <dcterms:created xmlns:dcterms="http://purl.org/dc/terms/" xsi:schemaLocation="http://purl.org/dc/terms/ http://dublincore.org/schemas/xmls/qdc/dcterms.xsd">2025-04-30T20:02:55Z</dcterms:created>
   </d:DIDLInfo>
   <d:Item id="hdl_10230_70235">
      <d:Descriptor>
         <d:Statement mimeType="application/xml; charset=utf-8">
            <dii:Identifier xmlns:dii="urn:mpeg:mpeg21:2002:01-DII-NS" xsi:schemaLocation="urn:mpeg:mpeg21:2002:01-DII-NS http://standards.iso.org/ittf/PubliclyAvailableStandards/MPEG-21_schema_files/dii/dii.xsd">urn:hdl:10230/70235</dii:Identifier>
         </d:Statement>
      </d:Descriptor>
      <d:Descriptor>
         <d:Statement mimeType="application/xml; charset=utf-8">
            <oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
               <dc:title>Immune cell subpopulations and serum neurofilament light chain are associated with increased risk of disease worsening in multiple sclerosis</dc:title>
               <dc:creator>Brune-Ingebretsen, Synne</dc:creator>
               <dc:creator>Høgestøl, Einar A.</dc:creator>
               <dc:creator>de Rosbo, Nicole Kerlero</dc:creator>
               <dc:creator>Berg-Hansen, Pål</dc:creator>
               <dc:creator>Brunborg, Cathrine</dc:creator>
               <dc:creator>Blennow, Kaj</dc:creator>
               <dc:creator>Zetterberg, Henrik</dc:creator>
               <dc:creator>Paul, Friedemann</dc:creator>
               <dc:creator>Uccelli, Antonio</dc:creator>
               <dc:creator>Villoslada, Pablo</dc:creator>
               <dc:creator>Harbo, Hanne F.</dc:creator>
               <dc:creator>Berge, Tone</dc:creator>
               <dc:subject>Multiple sclerosis</dc:subject>
               <dc:subject>Serum neurofilament light chain</dc:subject>
               <dc:subject>Immune cell subset frequencies</dc:subject>
               <dc:subject>Biomarkers</dc:subject>
               <dc:subject>Disease worsening</dc:subject>
               <dc:description>Changes is lymphocyte subpopulations in peripheral blood have been proposed as biomarkers for evaluation of disease activity in multiple sclerosis (MS). Serum neurofilament light chain (sNfL) is a biomarker reflecting neuro-axonal injury in MS that could be used to monitor disease activity, response to drugs and to prognosticate disease course. Here we show a moderate correlation between sNfL and lymphocyte cell subpopulations, and our data furthermore suggest that sNfL and specific immune cell subpopulations together could predict future disease worsening in MS.</dc:description>
               <dc:description>This work was supported by the European Commission (ERACOSYSMED ERA-Net program, Sys4MS project, id:43), Instituto de Salud Carlos III, Spain (AC1500052), the Italian Ministry of Health (WFR-PER-2013-02361136), the German Ministry of Science (Deutsches Teilprojekt B “Förderkennzeichen”: 031L0083B), the Norwegian Research Council (project 257955), the South-Eastern Norway Regional Health Authority (project 2019111) and Biogen Norway. Henrik Zetterberg is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2022-01018), the European Union's Horizon Europe research and innovation programme under grant agreement No 101053962, and Swedish State Support for Clinical Research (#ALFGBG-71320).</dc:description>
               <dc:date>2025-04-30T20:02:55Z</dc:date>
               <dc:date>2025-04-30T20:02:55Z</dc:date>
               <dc:date>2025-04-29T09:44:34Z</dc:date>
               <dc:date>2025-04-29T09:44:34Z</dc:date>
               <dc:date>2023</dc:date>
               <dc:type>info:eu-repo/semantics/article</dc:type>
               <dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
               <dc:identifier>http://hdl.handle.net/10230/70235</dc:identifier>
               <dc:relation>Journal of Neuroimmunology. 2023 Sep;382:578175</dc:relation>
               <dc:relation>info:eu-repo/grantAgreement/EC/H2020/101053962</dc:relation>
               <dc:rights>© 2023 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</dc:rights>
               <dc:rights>http://creativecommons.org/licenses/by/4.0/</dc:rights>
               <dc:rights>http://creativecommons.org/licenses/by/4.0/</dc:rights>
               <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
               <dc:publisher>Elsevier</dc:publisher>
            </oai_dc:dc>
         </d:Statement>
      </d:Descriptor>
   </d:Item>
</d:DIDL></metadata></record></GetRecord></OAI-PMH>